Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T39677
|
||||
| Former ID |
TTDR00692
|
||||
| Target Name |
Bile-salt-activated lipase
|
||||
| Gene Name |
CEL
|
||||
| Synonyms |
BAL; BSSL; Bile-salt-stimulated lipase; Carboxyl ester lipase; Cholesterol esterase; Pancreatic cholesterol esterase; Pancreatic lysophospholipase; Sterol esterase; CEL
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Exocrine pancreatic insufficiency [ICD10: K86.8] | ||||
| Hypercholesterolemia [ICD10: E78] | |||||
| Pancreatic disease [ICD10: K85-K86] | |||||
| Type 2 diabetes [ICD9: 250; ICD10: E11] | |||||
| Function |
Catalyzes fat and vitamin absorption. Acts in concert with pancreatic lipase and colipase for the complete digestion of dietary triglycerides.
|
||||
| BioChemical Class |
Carboxylic ester hydrolase
|
||||
| UniProt ID | |||||
| EC Number |
EC 3.1.1.3
|
||||
| Sequence |
MGRLQLVVLGLTCCWAVASAAKLGAVYTEGGFVEGVNKKLGLLGDSVDIFKGIPFAAPTK
ALENPQPHPGWQGTLKAKNFKKRCLQATITQDSTYGDEDCLYLNIWVPQGRKQVSRDLPV MIWIYGGAFLMGSGHGANFLNNYLYDGEEIATRGNVIVVTFNYRVGPLGFLSTGDANLPG NYGLRDQHMAIAWVKRNIAAFGGDPNNITLFGESAGGASVSLQTLSPYNKGLIRRAISQS GVALSPWVIQKNPLFWAKKVAEKVGCPVGDAARMAQCLKVTDPRALTLAYKVPLAGLEYP MLHYVGFVPVIDGDFIPADPINLYANAADIDYIAGTNNMDGHIFASIDMPAINKGNKKVT EEDFYKLVSEFTITKGLRGAKTTFDVYTESWAQDPSQENKKKTVVDFETDVLFLVPTEIA LAQHRANAKSAKTYAYLFSHPSRMPVYPKWVGADHADDIQYVFGKPFATPTGYRPQDRTV SKAMIAYWTNFAKTGDPNMGDSAVPTHWEPYTTENSGYLEITKKMGSSSMKRSLRTNFLR YWTLTYLALPTVTDQEATPVPPTGDSEATPVPPTGDSETAPVPPTGDSGAPPVPPTGDSG APPVPPTGDSGAPPVPPTGDSGAPPVPPTGDSGAPPVPPTGDSGAPPVPPTGDSGAPPVP PTGDSGAPPVPPTGDAGPPPVPPTGDSGAPPVPPTGDSGAPPVTPTGDSETAPVPPTGDS GAPPVPPTGDSEAAPVPPTDDSKEAQMPAVIRF |
||||
| Drugs and Mode of Action | |||||
| Drug(s) | Bucelipase alfa | Drug Info | Phase 3 | Exocrine pancreatic insufficiency | [1] |
| Taurocholic Acid | Drug Info | Phase 1/2 | Type 2 diabetes | [2] | |
| CVT-1 | Drug Info | Terminated | Hypercholesterolemia | [3] | |
| Modulator | Bucelipase alfa | Drug Info | [4] | ||
| CVT-1 | Drug Info | [3] | |||
| TgBSSL | Drug Info | [5] | |||
| Inhibitor | compound 10f | Drug Info | [6] | ||
| compound 10l | Drug Info | [6] | |||
| Taurocholic Acid | Drug Info | [7] | |||
| Pathways | |||||
| BioCyc Pathway | Triacylglycerol degradation | ||||
| WikiPathways | Lipid digestion, mobilization, and transport | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01413581) Comparison of rhBSSL With Placebo When Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants. U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4547). | ||||
| REF 3 | Lack of effect of cholesterol esterase inhibitor CVT-1 on cholesterol absorption and LDL cholesterol in humans. Cardiovasc Drugs Ther. 1999 Sep;13(5):449-54. | ||||
| REF 4 | ClinicalTrials.gov (NCT00743483) Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency. U.S. National Institutes of Health. | ||||
| REF 5 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2872). | ||||
| REF 6 | Synthesis and evaluation of 2-(1H-indol-3-yl)-4-phenylquinolines as inhibitors of cholesterol esterase. Bioorg Med Chem Lett. 2014 Mar 15;24(6):1545-9. | ||||
| REF 7 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.